This project intends to carry out a proof of concept of biod technology for its application to the detection of biomarkers related to Alzheimer’s disease (TAU and beta-amyloid protein).
- RESEARCH TYPE Development of a reading platform for in-vitro diagnostics
- RESEARCH YEAR 2016
In this project we will experimentally test and validate a PoC device based on our technology for the simultaneous measurement of three biomarkers (proteins MMP9, S100A6 and CST4) associated with the ophthalmological pathology of dry eye.
In this project we will experimentally test and validate a PoC device based on our technology for the simultaneous measurement of three biomarkers associated with ophthalmological pathologies, more specifically to the pathology of “dry eye”, counting on the Center’s experience and know-how of Biomedical Technology of the UPM and, more specifically, of the Laboratory of Optics, Photonics and Biophotonics, in the optimization of the biofunctionalization and recognition protocols for the performance of bioassays without marking, as well as the development of the calibration curves for different bio -Applications. Part of the researchers that are part of this group of the CTB are authors of the aforementioned patents, so that their advice and technical assistance will be crucial for the validation of the reading device developed in BIOD.
The result will be a prototype capable of quantitatively and simultaneously measuring three biomarkers (proteins MMP9, S100A6 and CST4) associated with dry eye pathology, using only 1 micro-liter sample (human tear), offering the results in concentration measurements and in a time of about 20 minutes, including incubation and reading.